1-5 of 5
Xiaohong Zhao, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CDK9 As a New Therapeutic Vulnerability for Ibrutinib Resistance Mantle Cell Lymphoma (MCL)

Michelle Wang, BSE, Xiaohong Zhao, MD PhD, Huijuan Jiang, MD, Joy Catherine Yan, Eduardo Sotomayor, MD, Kenneth H. Shain, MD PhD, Bijal Shah, MD, Jianguo Tao, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 34–35.
https://doi.org/10.1182/blood-2020-141386
Published: 2020
Journal Articles

Pharmaocogenomic Characterization of MCL-1 Inhibitor Response and Resistance in Aggressive B-Cell Lymphomas

Michelle Wang, BSE, Tao Li, MD, Yuan Ren, PhD, Bijal Shah, MD, Tint Lwin, MD PhD, Jing Gao, PhD, Kenneth H. Shain, MD PhD, Wei Zhang, PhD, Xiaohong Zhao, MD PhD, Jianguo Tao, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–21.
https://doi.org/10.1182/blood-2020-141407
Published: 2020
Journal Articles

Pharmacoproteomics Identifies PLK1 As Vulnerability for Aggressive B-Cell Lymphomas

Yuan Ren, PhD, Chengfeng Bi, MD PhD, Xiaohong Zhao, MD PhD, Tint Lwin, MD PhD, Wang Cheng, MD, Ji Yuan, Ariosto Siqueira Silva, PhD, Bijal D. Shah, MD, Bin Fang, PhD, Tao Li, John M. Koomen, PhD, Huijuan Jiang, MD, Julio C. Chavez, MD, Lan V. Pham, PhD, Praneeth Reddy Sudalagunta, PhD, Lixin Wan, Xuefeng Wang, PhD, William S. Dalton, PhD MD, Lynn C. Moscinski, MD, Kenneth H. Shain, MD PhD, Julie M. Vose, MD MBA, John Cleveland, PhD, Eduardo Sotomayor, MD, Kai Fu, MD PhD, Jianguo Tao, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2853.
https://doi.org/10.1182/blood-2018-99-118004
Published: 2018
Journal Articles

Targeting Kinome Reprogramming for Overcoming Ibrutinib-Resistance (IR) in Mantle Cell Lymphoma (MCL)

Xiaohong Zhao, MD PhD, Huijuan Jiang, MD, Michelle Wang, Tao Li, MD, Jing Gao, PhD, Tint Lwin, MD PhD, Yuan Ren, PhD, Eduardo Sotomayor, MD, Bijal D. Shah, MD, Jianguo Tao, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2651.
https://doi.org/10.1182/blood-2018-99-116756
Published: 2018
Journal Articles

Venetoclax As a Single Agent and in Combination with PI3K-mTOR1/2 Kinase Inhibitors Against Ibrutinib Sensitive and Resistant Mantle Cell Lymphoma

Huijuan Jiang, MD, Tint Lwin, MD PhD, Bijal D. Shah, MD, Grace T Li, Yuan Ren, Michael W Yan, Lynn C. Moscinski, MD, Xiaohong Zhao, MD PhD, Jianguo Tao, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5197.
https://doi.org/10.1182/blood.V130.Suppl_1.5197.5197
Published: 2017